Analysis: China’s biotech sector comes of age with big licensing deals, global ambitions

If investors in China’s biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd (9995.HK) struck last month with Seattle-based Seagen Inc …

( read original story …)